155 related articles for article (PubMed ID: 19686789)
21. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin.
Chow DS; Gong L; Wolfe MD; Giovanella BC
Ann N Y Acad Sci; 2000; 922():164-74. PubMed ID: 11193891
[TBL] [Abstract][Full Text] [Related]
22. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
23. Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously.
Qi X; Fan Y; He H; Wu Z
Carbohydr Polym; 2015 Aug; 126():231-9. PubMed ID: 25933544
[TBL] [Abstract][Full Text] [Related]
24. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
[TBL] [Abstract][Full Text] [Related]
25. MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.
Fujita F; Koike M; Fujita M; Sakamoto Y; Okuno S; Kawaguchi T; Yano S; Yano T; Kiuchi S; Fujiwara T; Kudoh S; Kakushima M
Clin Cancer Res; 2005 Feb; 11(4):1650-7. PubMed ID: 15746070
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel.
Chang G; Ci T; Yu L; Ding J
J Control Release; 2011 Nov; 156(1):21-7. PubMed ID: 21777632
[TBL] [Abstract][Full Text] [Related]
27. Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.
Padhi S; Mirza MA; Verma D; Khuroo T; Panda AK; Talegaonkar S; Khar RK; Iqbal Z
Drug Deliv; 2016 Oct; 23(8):2827-2837. PubMed ID: 26548664
[TBL] [Abstract][Full Text] [Related]
28. Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes.
Zhang J; Shi W; Xue G; Ma Q; Cui H; Zhang L
Curr Drug Metab; 2020; 21(11):902-909. PubMed ID: 32851958
[TBL] [Abstract][Full Text] [Related]
29. F7 and topotecan co-loaded thermosensitive liposome as a nano-drug delivery system for tumor hyperthermia.
Du C; Li S; Li Y; Galons H; Guo N; Teng Y; Zhang Y; Li M; Yu P
Drug Deliv; 2020 Dec; 27(1):836-847. PubMed ID: 32508162
[TBL] [Abstract][Full Text] [Related]
30. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design.
Vali AM; Toliyat T; Shafaghi B; Dadashzadeh S
Drug Dev Ind Pharm; 2008 Jan; 34(1):10-23. PubMed ID: 18214751
[TBL] [Abstract][Full Text] [Related]
31. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
32. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
34. Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo.
Nie T; Wong CC; Alston N; Aro P; Constantinides PP; Rigas B
Br J Pharmacol; 2012 Jun; 166(3):991-1001. PubMed ID: 22141583
[TBL] [Abstract][Full Text] [Related]
35. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
36. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
37. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Saito R; Krauze MT; Noble CO; Drummond DC; Kirpotin DB; Berger MS; Park JW; Bankiewicz KS
Neuro Oncol; 2006 Jul; 8(3):205-14. PubMed ID: 16723630
[TBL] [Abstract][Full Text] [Related]
38. Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours.
Centelles MN; Wright M; So PW; Amrahli M; Xu XY; Stebbing J; Miller AD; Gedroyc W; Thanou M
J Control Release; 2018 Jun; 280():87-98. PubMed ID: 29723616
[TBL] [Abstract][Full Text] [Related]
39. Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor in vitro and in vivo.
Yu XW; Lin S; Du HZ; Zhao RP; Feng SY; Yu BY; Zhang LY; Li RM; Qian CM; Luo XJ; Yuan ST; Sun L
Oncotarget; 2016 May; 7(22):32990-3003. PubMed ID: 27105508
[TBL] [Abstract][Full Text] [Related]
40. Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer.
Kuehl PJ; Yingling CM; Dubose D; Burke M; Revelli DA; Chen W; Dye WW; Belinsky SA; Tessema M
Drug Deliv; 2021 Dec; 28(1):767-775. PubMed ID: 33860729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
